MANAGEMENT OF PATIENTS WITH HEMOPHILIA A ON EMICIZUMAB PROPHYLACTIC TREATMENT: RECOMMENDATION FROM RUSSIAN EXPERTS

被引：0

作者：

Andreeva, T. A. ^{[1
]}

Zharkov, P. A. ^{[3
]}

Zozulya, N., I ^{[4
]}

Zorenko, V. Yu ^{[4
]}

Konstantinova, V. N. ^{[1
]}

Lebedev, V. V. ^{[2
]}

Mamaev, A. N. ^{[5
]}

Markova, I., V ^{[6
]}

Petrov, V. Yu ^{[7
]}

Polyanskaya, T. Yu ^{[8
]}

Schiller, E. E. ^{[9
]}

机构：

[1] Hematologist Head City Ctr Treatment Patients, City Polyclin 37, St Petersburg 191186, Russia

[2] Childrens Reg Clin Hosp, Head Childrens Reg Oncohematol Ctr, Minist Hlth Krasnodar Reg, Krasnodar 350007, Russia

[3] Dmitriy Rogachev Natl Med Res Ctr Pediat Hematol, Hematologist Consultat Dept, Pediatrician Short Term Treatment Inpatient Dept, Moscow 117997, Russia

[4] Natl Med Res Ctr Hematol, Head Dept Hemostasis Disorders, Moscow 125167, Russia

[5] Natl Med Res Ctr Hematol, Altai Div, Minist Hlth Russian Federat, Moscow 125167, Russia

[6] Raisa Gorbacheva Mem Res Inst Pediat Oncol Hemato, St Petersburg 1999022, Russia

[7] Morozovskaya Childrens City Clin Hosp, Moscow Hlth Dept, Hematologist Hematol Dept, Moscow 119049, Russia

[8] Natl Res Ctr Hematol, Dept Traumatol & Orthoped, Moscow 125167, Russia

[9] Odintsovo Reg Hosp, Head Children Hematol Dept, Odintsovo 143003, Russia

来源：

GEMATOLOGIYA I TRANSFUZIOLOGIYA | 2022年 / 67卷 / 02期

关键词：

emicizumab; hemophilia; factor VIII; factor VIII inhibitor; BISPECIFIC ANTIBODY; INHIBITORS; BLEEDS;

D O I：

10.35754/0234-5730-2022-67-2-267-280

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction. In 2018 emicizumab was approved in Russia for prophylactic treatment in patients with hemophilia A (HA) with inhibitors and in 2019 for patients with severe HA without inhibitors. A significant amount of data has been accumulated from clinical trials and real-world data, which allow us to resolve most of the questions that hematologists may have when to prescribe emicizumab. Aim - to provide information on the management of patients on emicizumab. Results. The recommendations accumulated the currently available information and world experience in the management of patients receiving emicizumab in order to facilitate decision-making when prescribing and using emicizumab. Information on the use of emicizumab in patients with HA with FVIII inhibitors and severe HA without FVIII inhibitors is presented. Possible complications and measures for their prevention and treatment are presented.

引用

页码：267 / 280

页数：14

共 48 条

[31] Health-related quality of life and its associated factors among hemophilia patients: experience from Ethiopian Hemophilia Treatment Centre
Iyar, Sitina
Gebremariam, Girma Tekle
Beyene, Dessale Abate
Gebremedhin, Amha
Tadesse, Tamrat Assefa
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2024, 10 (01)
[32] Health-related quality of life and its associated factors among hemophilia patients: experience from Ethiopian Hemophilia Treatment Centre
Sitina Iyar
Girma Tekle Gebremariam
Dessale Abate Beyene
Amha Gebremedhin
Tamrat Assefa Tadesse
Journal of Pharmaceutical Health Care and Sciences, 10
[33] Quantifying Benefit-Risk Trade-Offs Toward Prophylactic Treatment Among Adult Patients With Hemophilia A in China: Discrete Choice Experiment Study
Wang, Limin
Liu, Shimeng
Jiang, Shan
Li, Chaofan
Lu, Liyong
Fang, Yunhai
Li, Shunping
JMIR PUBLIC HEALTH AND SURVEILLANCE, 2023, 9
[34] Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee
Collins, P. W.
Liesner, R.
Makris, M.
Talks, K.
Chowdary, P.
Chalmers, E.
Hall, G.
Riddell, A.
Percy, C. L.
Hay, C. R.
Hart, D. P.
HAEMOPHILIA, 2018, 24 (03) : 344 - 347
[35] Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study
Collins, P.
Faradji, A.
Morfini, M.
Enriquez, M. M.
Schwartz, L.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (01) : 83 - 89
[36] Resource utilization and treatment costs of patients with severe hemophilia A: Real-world data from the ATHNdataset
Recht, Michael
He, Chunla
Chen, Er
Cheng, Dunlei
Solari, Paul
Hinds, David
EJHAEM, 2022, 3 (02): : 341 - 352
[37] Comparison of spontaneous bleeding incidents despite use of prophylactic factor treatments in the era of emicizumab use over 12 months for patients with moderate or severe haemophilia A in an adult haemophilia treatment centre South Australia
Lin, Yu-Hsuan
HAEMOPHILIA, 2024, 30 : 137 - 138
[38] Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US
Lewandowska, Magdalena
Randall, Nicole
Bakeer, Nihal
Maahs, Jennifer
Sagar, Jeanne
Greist, Anne
Shapiro, Amy D.
HAEMOPHILIA, 2021, 27 (01) : 90 - 99
[39] Better Communication for Better Management of Persons with Hemophilia: Results from a Patients'-Clinicians' Project to Address the New Therapeutic Landscape
Banov, Laura
Linari, Silvia
Ambroso, Luigi
Ferri Grazzi, Enrico
Gallo, Samanta
Pasqualetti, Patrizio
Mancuso, Maria Elisa
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)
[40] Endothelial cells derived from patients' induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia A
Rose, Melanie
Gao, Kewa
Cortez-Toledo, Elizabeth
Agu, Emmanuel
Hyllen, Alicia A.
Conroy, Kelsey
Pan, Guangjin
Nolta, Jan A.
Wang, Aijun
Zhou, Ping
STEM CELLS TRANSLATIONAL MEDICINE, 2020, 9 (06) : 686 - 696

← 1 2 3 4 5 →